Filing Details
- Accession Number:
- 0001801385-23-000004
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-05-23 16:23:20
- Reporting Period:
- 2023-05-19
- Accepted Time:
- 2023-05-23 16:23:20
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1711279 | Krystal Biotech Inc. | KRYS | Biological Products, (No Disgnostic Substances) (2836) | 821080209 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1801385 | Kathryn Romano | C/O Krystal Biotech, Inc. 2100 Wharton Street, Suite 701 Pittsburgh PA 15203 | Chief Accounting Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-05-19 | 12,500 | $52.26 | 28,484 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-05-19 | 12,500 | $95.05 | 15,984 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2023-05-19 | 12,500 | $52.26 | 28,484 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-05-19 | 12,500 | $95.04 | 15,984 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-05-19 | 3,428 | $95.08 | 12,556 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2023-05-22 | 2,521 | $52.26 | 15,077 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-05-22 | 2,521 | $105.80 | 12,556 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2023-05-22 | 2,570 | $52.26 | 15,126 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-05-22 | 2,570 | $106.81 | 12,556 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2023-05-22 | 1,300 | $52.26 | 13,856 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-05-22 | 1,300 | $107.88 | 12,556 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2023-05-22 | 2,955 | $52.26 | 15,511 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-05-22 | 2,955 | $109.17 | 12,556 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2023-05-22 | 3,154 | $52.26 | 15,710 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-05-22 | 3,154 | $109.99 | 12,556 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2023-05-22 | 12,500 | $63.55 | 25,056 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-05-22 | 12,500 | $110.00 | 12,556 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-05-19 | 12,500 | $0.00 | 12,500 | $52.26 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-05-19 | 12,500 | $0.00 | 12,500 | $52.26 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-05-22 | 12,500 | $0.00 | 12,500 | $52.26 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-05-22 | 12,500 | $0.00 | 12,500 | $63.55 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 37,500 | 2030-01-30 | No | 4 | M | Direct | |
| 25,000 | 2030-01-30 | No | 4 | M | Direct | |
| 12,500 | 2030-01-30 | No | 4 | M | Direct | |
| 37,500 | 2032-02-27 | No | 4 | M | Direct |
Footnotes
- The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $95.00 per share.
- The transaction was executed in multiple trades ranging from $95.0000 to $95.3800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates sales of 3,428 shares with a limit price of $95.00 per share.
- The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $105.00 per share.
- The transaction was executed in multiple trades ranging from $105.3400 to $106.3100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- The transaction was executed in multiple trades ranging from $106.3700 to $107.0300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- The transaction was executed in multiple trades ranging from $107.6900 to $108.4200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- The transaction was executed in multiple trades ranging from $108.9000 to $109.5500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- The transaction was executed in multiple trades ranging from $109.9700 to $110.0000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $110.00 per share.
- The transaction was executed in a single trade.
- 50,000 options were granted that vest in four equal annual installments beginning on January 21, 2021.
- 50,000 options were granted that vest in four equal annual installments beginning on February 28, 2023.
Billionaire Hedge Funds
